Rivals no more? Merck, Pfizer partner on SGLT2 inhibitor
This article was originally published in Scrip
Executive Summary
If you're the maker of a top-selling diabetes drug, why wouldn't you collaborate with a company that also may have a diabetes blockbuster on its hands, even if the partner normally is your biggest rival?